DFCM
PVLA icon

Dark Forest Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Dark Forest Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,606
Closed -$200K – 1079
2026
Q1 		$200K Buy
+1,606
New +$168K 0.02% 741

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Dark Forest Capital Management's PVLA Position: Q2 2026 in Review

Dark Forest Capital Management sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 1,606 shares — an estimated $200K sold.

Dark Forest Capital Management first reported a position in PVLA in Q1 2026 and held it in 1 quarter. The position peaked at $200K in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Dark Forest Capital Management reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dark Forest Capital Management sold 1,606 Palvella Therapeutics shares in Q2 2026, an estimated $200K.
  • Dark Forest Capital Management first reported a position in Palvella Therapeutics in Q1 2026 and held it in 1 quarter.
  • Dark Forest Capital Management's Palvella Therapeutics position peaked at $200K in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Dark Forest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.